Jan Mikkelsen, Ascendis Pharma president and CEO
After first FDA win last year, Ascendis touts a new PhIII success in hypoparathyroidism
After achieving its first FDA approval last summer, Ascendis Pharma believes it’s approaching a second in the near future.
The Danish biotech touted topline …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
